UBS Asset Management Americas Inc. Has $513.34 Million Holdings in Eli Lilly and Company (LLY)
UBS Asset Management Americas Inc. lessened its holdings in Eli Lilly and Company (NYSE:LLY) by 9.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,237,388 shares of the company’s stock after selling 651,575 shares during the quarter. UBS Asset Management Americas Inc. owned 0.59% of Eli Lilly and worth $513,337,000 as of its most recent SEC filing.
A number of other institutional investors have also made changes to their positions in LLY. Ingalls & Snyder LLC increased its holdings in Eli Lilly and by 2.7% in the 1st quarter. Ingalls & Snyder LLC now owns 18,452 shares of the company’s stock valued at $1,552,000 after buying an additional 480 shares during the period. Family Legacy Inc. bought a new stake in Eli Lilly and in the 1st quarter valued at $492,000. Northwestern Mutual Investment Management Company LLC increased its holdings in Eli Lilly and by 75.9% in the 1st quarter. Northwestern Mutual Investment Management Company LLC now owns 196,271 shares of the company’s stock valued at $16,508,000 after buying an additional 84,718 shares during the period. BP PLC increased its holdings in Eli Lilly and by 61.4% in the 1st quarter. BP PLC now owns 113,000 shares of the company’s stock valued at $9,504,000 after buying an additional 43,000 shares during the period. Finally, Northwestern Mutual Wealth Management Co. increased its holdings in Eli Lilly and by 4.7% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 70,996 shares of the company’s stock valued at $5,971,000 after buying an additional 3,216 shares during the period. 75.68% of the stock is currently owned by hedge funds and other institutional investors.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 205,000 shares of the company’s stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $86.81, for a total transaction of $17,796,050.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Over the last 90 days, insiders have sold 770,000 shares of company stock worth $64,669,850. Corporate insiders own 0.20% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://www.watchlistnews.com/ubs-asset-management-americas-inc-has-513-34-million-holdings-in-eli-lilly-and-company-lly/1697371.html.
Eli Lilly and Company (NYSE:LLY) opened at $83.29 on Friday. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66. Eli Lilly and Company has a 52-week low of $64.18 and a 52-week high of $89.09. The stock has a market cap of $91,710.20, a PE ratio of 20.36, a price-to-earnings-growth ratio of 1.83 and a beta of 0.34.
Eli Lilly and (NYSE:LLY) last released its earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.03 by $0.02. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The company had revenue of $5.66 billion for the quarter, compared to the consensus estimate of $5.52 billion. During the same period in the prior year, the company posted $0.88 EPS. The company’s revenue was up 9.0% compared to the same quarter last year. equities research analysts anticipate that Eli Lilly and Company will post 4.22 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th will be given a dividend of $0.52 per share. The ex-dividend date is Tuesday, November 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.50%. Eli Lilly and’s payout ratio is presently 98.58%.
Several brokerages have recently commented on LLY. Morgan Stanley set a $86.00 target price on shares of Eli Lilly and and gave the company a “hold” rating in a research note on Friday, October 6th. Leerink Swann boosted their target price on shares of Eli Lilly and from $92.00 to $93.00 and gave the company a “market perform” rating in a research note on Monday, October 23rd. BMO Capital Markets set a $73.00 target price on shares of Eli Lilly and and gave the company a “sell” rating in a research note on Tuesday, October 24th. Credit Suisse Group downgraded shares of Eli Lilly and from an “outperform” rating to a “neutral” rating and boosted their target price for the company from $84.23 to $88.00 in a research note on Tuesday, October 10th. Finally, Goldman Sachs Group, Inc. (The) restated a “buy” rating and issued a $95.00 target price (up previously from $92.00) on shares of Eli Lilly and in a research note on Thursday, October 5th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have assigned a buy rating to the company. Eli Lilly and currently has a consensus rating of “Hold” and a consensus target price of $89.76.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.